Abstract
The evolution of drug resistance in bacteria depends on a rapid mutation rate. However, drug resistance mutations frequently incur a cost to the microbe, usually a reduced growth rate. Unfortunately, this cost cannot be exploited because those crafty microbes usually develop compensatory mutations, which offset the growth disadvantage while maintaining drug resistance. In a Perspective, Bull and Levin discuss new findings ( BjA¶rkman et al. ) showing that different compensatory mutations evolve depending on whether pathogenic bacteria are grown in culture or in an animal host. They caution that care should be taken when trying to extrapolate in vitro findings about bacterial drug resistance to in vivo situations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
